ClinicalTrials.gg
RecruitingNCT05991336Updated Nov 4, 2026

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

An observational study in Transfusion-dependent Beta-Thalassemia and Gene Therapy, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 3 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Nov 4, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
3 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Planned enrollment
5th of 10
100 · median 96
Started
2023
with 10 others
Observational
10 of 44
8 open now
Primary completion
2027-12
later than 14 of 24 live
Registered
26th of 44
by date
Lead sponsor
6 of 44
Institute of Hematology & Blood Diseases Hospital, China

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 11 that started in 2023, is one of 10 observational ones, reaches primary completion later than 14 of the 24 other live ones, and was the 26th registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 3 Years to 14 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

The investigate will conduct a cohort study to compare the growth and development, metabolism, lifestyle behavior, and health-related quality of life among three groups: children with transfusion-dependent β-thalassemia (TDT) who have received gene therapy, TDT children with lifelong supportive therapy and healthy children.

03

Conditions studied

  • Transfusion-dependent Beta-Thalassemia
  • Gene Therapy

Browse trials for

Keywords

  • Transfusion-dependent Beta-Thalassemia
  • gene therapy
  • cohort study
  • case-control
04

Who can participate

Ages eligible
3 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants are divided into three groups: TDT children who have received gene therapy, TDT children who have received lifelong supportive therapy, and healthy children.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Gene therapy group-inclusion

  • Male or female age of 3-14 years
  • TDT Children who have received gene therapy.
  • Subjects who are willing and able to provide written .

Supportive therapy group-inclusion

  • Gender same as the matched case
  • Age similar to the matched case
  • Children with β-TDT
  • No history of gene therapy or hematopoietic stem cell transplantation
  • Subjects who are willing and able to provide written informed consent.

Healthy children group-inclusion

  • Gender same as the matched case
  • Age similar to the matched case
  • Subjects who are willing and able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of compound α-thalassemia
  • Uncontrolled systemic fungal, bacterial, or viral infection
  • History of malignant solid tumors, myeloproliferative or immunodeficiency diseases
  • Diagnosed with mental illness
  • Patients considered to be ineligible for the study by the investigator for reasons other than the above

Discontinuation of Study :

  • Subjects who are unwilling or unable to continue participating in the study (withdrawal of ) may withdraw from the study
  • Subjects who received gene therapy or hematopoietic stem cell transplantation during the study
  • The subject is seriously non-compliant with the study requirements, such as missing 2 consecutive visits
  • Subject lost to follow-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Gene therapy group

    TDT Children who have received gene therapy between 3\~14 years old.

    Genetic: Gene therapy

  • Supportive therapy group

    TDT Children who received lifelong treatment with blood transfusions and iron chelation. They were selected based on the age and sex of the gene therapy group.

  • Healthy children group

    Healthy children were selected based on the age and sex of the gene therapy group.

Interventions

  • GeneticGene therapy

    Autologous edited hematopoietic stem cell transplantation

06

What researchers measure

Primary outcomes

  1. Growth in pediatric subjects will be assessed by height.

    Height in meters.

    Time frame: Up to 5 years.

  2. Growth in pediatric subjects will be assessed by weight.

    Weight in kilograms.

    Time frame: Up to 5 years.

  3. Growth in pediatric subjects will be assessed by bone density.

    Bone density measurement is measured by a procedure called densitometry, performed in the radiology medicine departments of hospitals or clinics. The result is the bone mineral density in grams per unit area (g/cm2).

    Time frame: Up to 5 years.

  4. The pubertal status will be measured using by Tanner scale.

    The Tanner scale, a well-known technique used to define pubertal stage, is based on physical measurements of development based on external primary and secondary sex characteristics (from Tanner 1: pre-pubertal to Tanner 5: mature adolescent).It was developed by Marshall and Tanner while conducting a longitudinal study during the 1940s to the 1960s in England. Based on observational data, they developed separate scales for the development of external genitalia: phallus, scrotum, and testes volume in males; breasts in females; and pubic hair in both males and females.

    Time frame: Up to 5 years.

  5. Quality of life will be measured using by Pediatric Quality of Life Inventory (PedsQL) at baseline and the end of the study.

    The Pediatric Quality of Life Inventory (PedsQL) is a valid, standardized, generic, and self-reporting assessment tool to measure health-related quality of life HRQOL for pediatrics and adolescents. PedsQL contain 23-items, and consists of the following: physical functioning, emotional functioning, social functioning, and school functioning. Each item is scored on a 5-point scale, scores are linearly transformed to a 0-100 scale in which high score means better condition.

    Time frame: Up to 5 years.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2027, 54 months after the start.

Of 29 observational studies under beta-Thalassemia, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 156. This study's planned 54 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Dec 2028 → Dec 2027 and completion Dec 2029 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2023
First posted
Aug 14, 2023
StartActual
Jun 5, 2023
Primary completionEst.
Dec 31, 2027was Dec 2028
CompletionEst.
Dec 31, 2028was Dec 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Regenerative Medicine Center · Tianjin, China
Show 1 removed
  • Regenerative Medicine Center · Tianjin, China
Nov 4, 2026
Primary completion
Dec 31, 2028→Dec 31, 2027
Nov 4, 2026
Study completion
Dec 31, 2029→Dec 31, 2028
Nov 4, 2026
Primary outcomes
4 removed
What changed in the outcomes
  • RemovedGrowth in pediatric subjects will be assessed by the head and chest circumference.Time frame: Up to 5 years.
  • RemovedGrowth in pediatric subjects will be assessed by interocular distance.Time frame: Up to 5 years.
  • RemovedHormonal levels will be measured by clinical examination.Time frame: Up to 5 years.
  • RemovedLifestyle behaviors will be assessed by general questioning.Time frame: Up to 5 years.
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • Regenerative Medicine Center · Tianjin, China
    Show 1 removed
    • Regenerative Medicine Center · Tianjin, China
    Primary completion Dec 31, 2028→Dec 31, 2027
    Study completion Dec 31, 2029→Dec 31, 2028
    Primary outcomes 4 removed
    What changed in the outcomes
    • RemovedGrowth in pediatric subjects will be assessed by the head and chest circumference.Time frame: Up to 5 years.
    • RemovedGrowth in pediatric subjects will be assessed by interocular distance.Time frame: Up to 5 years.
    • RemovedHormonal levels will be measured by clinical examination.Time frame: Up to 5 years.
    • RemovedLifestyle behaviors will be assessed by general questioning.Time frame: Up to 5 years.
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05991336
Responsible party
Jun Shi (Director, Regenerative Medicine Clinic Center, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
Aug 14, 2023
Start date
Jun 5, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Jun Shi, PhD
Contact
shijun@ihcams.ac.cn
2223900913
Jingyu Zhao, MPH
Contact
zhaojingyu@ihcams.ac.cn
13752253515

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion